Vir Biotechnology, Inc.’s Post

Planning your pipeline management for 2024 and beyond? 📊💵 This is shaping up to be a make-or-break year for biotechs pushing clinical development for cell therapies amid the current investment landscape. Join Fenwick technology transactions partner Stefano Quintini and high-level decision-makers from biopharma leaders like Umoja Biopharma for a discussion spotlighting big pharma, venture capital, and investor perspectives on how to regain capital and safeguard clinical development for cell therapies in the current market. What burning question would you bring to the table? Join the conversation: https://bit.ly/3Ib9zYm #Healthcare #BioTech #Investing

Weekly #Biotech Activity Recap by Genenta Science (Nasdaq $GNTA) Last week saw U.S. equities climbing higher, with the S&P 500 and Nasdaq reaching record highs, continuing a trend of positive finishes for 15 out of the past 17 weeks. The S&P 500 surged by 1.7%, the Nasdaq by 1.4%, and the Dow by 1.3%. The biotech sector mirrored this upward trajectory, with the XBI index also rising by 1.7%. Amidst a quieter week for new issuances in the healthcare market, possibly due to holiday schedules, there was a notable follow-on offering. A single deal was executed, raising $211 million in total proceeds. This offering was for Iovance Biotherapeutics, which came on the heels of the FDA's accelerated approval for its advanced melanoma treatment, AMTAGVI. The offering, priced at the last sale, concluded the week with an impressive gain of +72.3%. As for IPO activity, the market took a pause with no new filings, pricings, or expected launches in the healthcare sector. Summary of Transactions: - Follow-on Offerings: Iovance Biotherapeutics, Inc. stood out with its $211 million offering, marking a significant uptick of +72.3% by the week's close, underscoring strong investor confidence post-FDA approval. No activity was reported in the blocks or convertible segments, indicating a focused week primarily on follow-on offerings within the healthcare ECM space.

March 04, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Akero’s $300 Million Public Offering BridgeBio’s $250 Million Public Offering Arcutis’s $173 Million Public Offering…More More Revance’s $100 Million Public Offering Nocion’s $62 Million Series B… More Armata’s $35 Million Debt Financing Nektar’s $30 Million Private Placement BioVie’s $21 Million Public Offering C4 Therapeutics $16 Million Upfront Fortress and Cyprium’s $4.1 Million NINDS Grant Bone’s $2 Million Public Offering

good article in todays The Australian Financial Review on #asx #biotech sector. Hugh Dive CFA the chief investment officer at Atlas Funds Management says picking biotech winners is tricky because each company is underpinned by inherently complex science and “So much rests on understanding the science, so you get a very binary outcome – either it works fabulously, or it goes to zero,” Some recent very good performers include Telix Pharmaceuticals Limited Clarity Pharmaceuticals. Recce Pharmaceuticals Ltd is also reporting excellent data from #clinicaltrials and looks set for a good run. congratulations BLINKLAB - Neurobehavioral Testing and Anton Uvarov PhD MBA on great #IPO. Here in Germany, European investors continue to look for quality ASX biotech stocks with a dual-listing in Germany. #biotechinvesting #pharma #impactinvesting #capitalmarkets #bourse #investorrelations

March 04, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Akero’s $300 Million Public Offering BridgeBio’s $250 Million Public Offering Arcutis’s $173 Million Public Offering…More More Revance’s $100 Million Public Offering Nocion’s $62 Million Series B… More Armata’s $35 Million Debt Financing Nektar’s $30 Million Private Placement BioVie’s $21 Million Public Offering C4 Therapeutics $16 Million Upfront Fortress and Cyprium’s $4.1 Million NINDS Grant Bone’s $2 Million Public Offering

A recent pick up in Biotech M&A activity is juxtaposed with record a high number of biotech bankruptcies. Are we at the end of the downward cycle?   #biotech #biotechdeals #venturecapital #mergersandacquisitions #LifeSciences #BiotechMarket #BiomedicalResearch

Recursion, a biotech firm which uses artificial intelligence to discover new drug candidates to acquire Exscientia, a technology-driven drug design and development company, for $688m. “We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers. Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started," Chris Gibson, Recursion Co-Founder and CEO. Exscientia (led by Dave H., Ben Taylor and Dan Ireland) is advised by Centerview Partners and A&O Shearman. Recursion (led by Chris Gibson, Michael Secora PhD and Nathan Hatfield) is advised by Allen & Company LLC. and Wilson Sonsini Goodrich & Rosati. #MergersAcquisitionsDivestitures #Pharmaceuticals #Biotechnology

#LSINW24 is 5 DAYS AWAY! Join us for an insightful panel discussion on how Washington can sustain our growth in biomanufacturing. Over the past decade, Washington has developed an innovative biomanufacturing sector and workforce. Unlike other region’s that have used tax incentives to attract large biopharmaceutical operations, Washington’s growth has come from the development of next generation facilities located close to R&D operations as well as the expansion of long-established facilities. In a competitive marketplace, what do we need to maintain the recent growth of biomanufacturing? This panel will explore workforce needs, how to support future innovation, as well as discuss the types of operations that are likely to grown in Washington vs. other regions and what we need to do to support them. Panelists include: • Snehal Patel, Executive Vice President and Head of Technical Operations, Sana Biotechnology, Inc. - Co-Moderator • Ryan Takeya, North Creek Site Head, Senior Director of Manufacturing, Pfizer - Co-Moderator • Ann Houseman, Vice President and Site Head, Bothell Cell Therapy Manufacturing Plant, Bristol Myers Squibb • Linda Zuckerman, Ph.D., Executive Vice President, Global Head of Biotherapeutics, Just - Evotec Biologics Register today before it's too late! https://lnkd.in/gtm893b9 #LifeScienceWashington #LifeScienceInnovationNW #SeattleConference #Biomanufacturing #WashingtonManufacturing

With two deals in six days, AbbVie has now inked the 3rd and 4th largest biopharma acquisitions of 2023 so far: Oct. 5: $110 million upfront for Parkinson's disease startup Mitokinin Nov. 30: $10.1 billion for decades-old ADC maker ImmunoGen Dec. 6: $8.7 billion for neuroscience biotech Cerevel Therapeutics CEO Rick Gonzalez hinted at the Chicago-area Big Pharma's appetite for more deals when discussing the ImmunoGen acquisition last Friday when he told analysts: "We have the financial wherewithal to do that if we found another asset that looked like this in neuroscience or anywhere else. We would act on it.” #abbvie #cerevel #pharma #biotech #acquisitions #mergersandacquisitions #dealmaking #drugdevelopment #neuroscienceresearch #schizophrenia #parkinsonsdisease Endpoints News

Deals are finally starting to happen